The online version of this article (doi:10.1186/ar3449) contains supplementary material, which is available to authorized users.
Dr. Clauw's financial disclosures are from Pfizer, Lilly, Forest, Cypress Biosciences, Pierre Fabre, UCB, Jazz Pharmaceuticals, and Merck. Dr. Phillips' financial disclosures are from Merck, United Therapeutics, and Actelion. Drs. Murphy and Williams declare that they do not have competing interests.
The idea for this manuscript arose from a meeting with all co-authors. SLM and AKL conducted the analysis with specific guidance from DAW. SLM provided an initial draft of the manuscript and all coauthors contributed intellectual content, participating in follow-up meetings and in the writing process. SLM acquired the data and assumes responsibility for the integrity of the data as well as the accuracy of the data analysis. All authors read and approved the final manuscript.
Although people with knee and hip osteoarthritis (OA) seek treatment because of pain, many of these individuals have commonly co-occurring symptoms (for example, fatigue, sleep problems, mood disorders). The purpose of this study was to characterize adults with OA by identifying subgroups with the above comorbid symptoms along with illness burden (a composite measure of somatic symptoms) to begin to examine whether subsets may have differing underlying pain mechanisms.
Community-living older adults with symptomatic knee and hip OA (n = 129) participated (68% with knee OA, 38% with hip OA). Hierarchical agglomerative cluster analysis was used. To determine the relative contribution of each variable in a cluster, multivariate analysis of variance was used.
We found three clusters. Cluster 1 (n = 45) had high levels of pain, fatigue, sleep problems, and mood disturbances. Cluster 2 (n = 38) had intermediate degrees of depression and fatigue, but low pain and good sleep. Cluster 3 (n = 42) had the lowest levels of pain, fatigue, and depression, but worse sleep quality than Cluster 2.
In adults with symptomatic OA, three distinct subgroups were identified. Although replication is needed, many individuals with OA had symptoms other than joint pain and some (such as those in Cluster 1) may have relatively stronger central nervous system (CNS) contributions to their symptoms. For such individuals, therapies may need to include centrally-acting components in addition to traditional peripheral approaches.
Arthritis prevalence and activity limitations--United States, 1990. MMWR Morb Mortal Wkly Rep. 1994, 43: 433-438.
Hannan MT, Felson DT, Pincus T: Analysis of the discordance between radiographic changes and knee pain in osteoarthritis of the knee. J Rheumatol. 2000, 27: 1513-1517. PubMed
Lethbridge-Cejku M, Scott WW, Reichle R, Ettinger WH, Zonderman A, Costa P, Plato CC, Tobin JD, Hochberg MC: Association of radiographic features of osteoarthritis of the knee with knee pain: data from the Baltimore Longitudinal Study of Aging. Arthritis Care Res. 1995, 8: 182-188. 10.1002/art.1790080311. CrossRefPubMed
Sale JEM, Gignac M, Hawker G: The relationship between disease symptoms, life events, coping and treatment, and depression among older adults with osteoarthritis. J Rheumatol. 2008, 35: 335-342. PubMed
Sagar DR, Staniaszek LE, Okine BN, Woodhams S, Norris LM, Pearson RG, Garle MJ, Alexander SPH, Bennett AJ, Barrett DA, Kendall DA, Scammell BE, Chapman V: Tonic modulation of spinal hyperexcitability by the endocannabinoid receptor system in a rat model of osteoarthritis pain. Arthritis Rheum. 2010, 62: 3666-3676. 10.1002/art.27698. PubMedCentralCrossRefPubMed
Hochman J, French M, Bermingham S, Hawker G: The nerve of osteoarthritis pain. Arthritis Care Res. 2010, 62: 1019-1023. 10.1002/acr.20142. CrossRef
Lee YC, Lu B, Bathon JM, Haythornthwaite JA, Smith MT, Page GG, Edwards RR: Pain sensitivity and pain reactivity in osteoarthritis. Arthritis Care Res (Hoboken). 2011, 63: 320-327. CrossRef
Gwilym SE, Keltner JR, Warnaby CE, Carr AJ, Chizh B, Chessell I, Tracey I: Psychophysical and functional imaging evidence supporting the presence of central sensitization in a cohort of osteoarthritis patients. Arthritis Care Res. 2009, 61: 1226-1234. 10.1002/art.24837. CrossRef
Chappell A, Desaiah D, Liu-Seifert H, Zhang S, Skljarevski V, Belenkov Y, Brown JP: A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract. 2011, 11: 33-41. 10.1111/j.1533-2500.2010.00401.x. CrossRefPubMed
Chappell A, Ossanna M, Liu-Seifert H, Iyengar S, Skljarevski V, Li L, Bennett RM, Collins H: Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain. 2009, 146: 253-260. 10.1016/j.pain.2009.06.024. CrossRefPubMed
Hudson JI, Pope HG: Fibromyalgia and psychopathology: is fibromyalgia a form of "affective spectrum disorder"?. J Rheumatol Suppl. 1989, 19: 15-22. PubMed
Murphy SL, Smith DM, Clauw DJ, Alexander NB: The impact of momentary pain and fatigue on physical activity in women with osteoarthritis. Arthritis Care Res. 2008, 59: 849-856. 10.1002/art.23710. CrossRef
Turk DC, Okifuji A, Sinclair JD, Starz TW: Pain, disability, and physical functioning in subgroups of patients with fibromyalgia. J Rheumatol. 1996, 23: 1255-1262. PubMed
Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, et al: Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986, 29: 1039-1049. 10.1002/art.1780290816. CrossRefPubMed
Goggins J, Baker K, Felson D: What WOMAC pain score should make a patient eligible for a trial in knee osteoarthritis?. J Rheumatol. 2005, 32: 540-542. PubMed
Andresen E, Malmgren J, Carter W, Patrick D: Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med. 1994, 10: 77-84. PubMed
Radloff L: The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Meas. 1977, 1: 385-401. 10.1177/014662167700100306. CrossRef
Wolfe F, Rasker J: The Symptom Intensity Scale, fibromyalgia, and the meaning of fibromyalgia-like symptoms. J Rheumatol. 2006, 33: 2291-2299. PubMed
Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatr Res. 1989, 28: 193-213. 10.1016/0165-1781(89)90047-4. CrossRef
Whitehouse SL, Crawford RW, Learmonth ID: Validation for the reduced Western Ontario and McMaster Universities Osteoarthritis Index function scale. J Orthop Surg. 2008, 16: 50-54.
Tabachnick BG, Fidell LS: Using Multivariate Statistics. 2007, Boston: Allyn and Bacon, 5
Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, et al: The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990, 33: 160-172. 10.1002/art.1780330203. CrossRefPubMed
Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P: The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010, 62: 600-610. 10.1002/acr.20140. CrossRef
Dominick KL, Golightly YM, Jackson GL: Arthritis prevalence and symptoms among US non-veterans, veterans, and veterans receiving Department of Veterans Affairs Healthcare. J Rheumatol. 2006, 33: 348-354. PubMed
- Subgroups of older adults with osteoarthritis based upon differing comorbid symptom presentations and potential underlying pain mechanisms
Susan L Murphy
Angela K Lyden
Daniel J Clauw
David A Williams
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II